Back

Apabetalone (RVX-208) inhibits key drivers of vascular inflammation, calcification, and plaque vulnerability through a BET-dependent epigenetic mechanism

3 September 2019 (08:30 - 12:30)
Organised by:
Congress Presentation Part of: Poster Session 6 - Coronary artery disease inflammation Inflammation and Immunity ESC Premium Access ESC Congress 2019

About the speaker

Photo
Doctor Ewelina Kulikowski

Calgary (Canada)

10 More presentations in this session

Presentation thumbnail
Doctor M. Karim (Oxford, GB)
Abstract Slides
Presentation thumbnail
Professor P. Pignatelli Spinazzola (Rome, IT)
Abstract Slides
Presentation thumbnail
Doctor D. Takagi (Kyouto, JP)
Abstract
Presentation thumbnail
Doctor H. Yamamoto (Kobe, JP)
Abstract Slides
Presentation thumbnail
Mrs H. Grauen Larsen (Malmo, SE)
Abstract

Access the full session

Session thumbnail
Poster Session 6 - Coronary artery disease inflammation

The Event

Event poster

ESC Congress 2019

3 September 2019 08:30 CET
You may be interested in
thumbnail
Congress Presentation
Epigenetic BET inhibitor apabetalone counters inflammatory and fibrotic processes in activated cardiac fibroblasts providing insight into reduced hospitalizations for heart failure in BETonMACE trial
1 September 2024
thumbnail
Congress Presentation
A proteomic atlas of atherosclerosis: regional proteomic signatures for plaque inflammation and calcification
30 April 2022
thumbnail
Congress Presentation
Pharmacological inhibition of histone demethylase 1A reduces oxidative stress and inflammation in the aorta of diabetic mice
23 May 2023
thumbnail
Congress Presentation
Atherosclerotic cardiovascular events associated with BTK inhibitors: a systematic review and meta-analysis of harms
20 June 2025

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources